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The rapid induction of alpha interferon (IFN-) and IFN- expression plays a critical role in the innate
immune response against viral infection. We studied the effects of transforming growth factor  (TGF-) and
its intracellular effectors, the Smads, on the function of IRF-7, an essential transcription factor for IFN- and
- induction. IRF-7 interacted with Smads, and IRF-7, but not IRF-3, cooperated with Smad3 to activate IFN-
transcription. This transcriptional cooperation occurred at the IRF-binding sequences in the IFN- promoter,
and dominant-negative interference with TGF- receptor signaling and Smad3 function decreased IRF-7-
mediated transcription. Furthermore, elimination of Smad3 expression in Smad3/ fibroblasts delayed and
decreased double-stranded RNA-induced expression of endogenous IFN-, whereas restoration of Smad3
expression enhanced IFN- induction. The IRF-7–Smad3 cooperativity resulted from the regulation of the
transactivation activity of IRF-7 by Smad3, and dominant-negative interference with Smad3 function decreased
IRF-7 activity. Consistent with the regulation by Smad3, the transcriptional activity of IRF-7 depended on and
was regulated by TGF- signaling. Our studies underscore a role of TGF-/Smad3 signaling in IRF-7-mediated
induction of IFN- expression.
Upon infection by viruses, cells activate the expression of
alpha and beta interferons (IFN- and -) as key components
of the innate immune response (25, 42, 77, 78). Following
transcriptional activation of the corresponding genes, infected
cells secrete these IFNs, which then bind to their cell surface
receptors. Consequent activation of the Jak-STAT signaling
pathway leads to induction of IFN target genes responsible for
a broad array of biological effects, including the antiviral re-
sponse (40, 75, 77). The Jak-STAT signaling mechanisms and
transcriptional activation by STATs are well characterized.
Much less is known about the signaling pathways that lead
from viral infection to transcriptional activation of the IFN-
and - genes. A double-stranded RNA intermediate generated
in the course of infection by many DNA and RNA viruses is
often considered a key component in the ability of viruses to
activate type I IFN expression; accordingly, synthetic double-
stranded poly(I-C) is commonly used as a potent inducer of
IFN- and - (10).
In contrast to the multiple IFN- genes, only one IFN-
gene exists in mice and humans. Extensive research during the
last few years has aimed at elucidating the mechanisms that
lead to the rapid transcriptional activation of the IFN- and -
genes in response to viral infection and has focused on the
IFN- promoter. Key players in their transcriptional activation
are IRF-3 and IRF-7, two structurally related members of the
IRF (IFN regulatory factors) family of transcription factors
(66, 76, 77, 90, 95). IRF-3 and IRF-7 are both required for
efficient induction of IFN-, and they cooperate with each
other as DNA-binding transcription factors at the promoter
(25, 41, 42, 77, 78). Both IRF-3 and IRF-7 are activated by
phosphorylation within their C-terminal segment and conse-
quent homo- or heterodimerization following virus infection
(3, 21, 49, 66, 68, 90). However, whereas IRF-3 is fully latent in
the absence of viral infection, IRF-7 has a basal activity that is
enhanced upon infection (21, 45, 66, 68, 90). Other extracel-
lular stimuli, including lipopolysaccharide, DNA damaging
agents, and UV light, also activate IRF-3 and IRF-7, most
likely through different mechanisms (67). While IRF-3 is con-
stitutively expressed in most cells, IRF-7 expression is induced
by exposure of cells to IFN (42, 77, 78). Most cells are thought
to express low levels of IFN- and - in the absence of virus
infection, thus providing a readiness to mediate a full IFN-/
response upon virus infection through a positive feedback
mechanism (77).
The IFN- promoter contains several positive and negative
regulatory cis elements. Among the four positive regulatory
domains (PRDs), designated PRDI through PRDIV, PRDIII
and PRDI are binding sequences for IRF-7 and IRF-3 as well
as other IRFs. The PRDII sequence is recognized by the tran-
scriptional activator NF-B, and the PRDIV sequence binds a
heterodimer of the basic leucine zipper proteins ATF-2 and
c-Jun (47, 56). Viral infection activates these transcription fac-
tors and leads to recruitment of the transcription coactivator
p300/CBP, the architectural factor HMGI (Y), and the assem-
bly of a multiprotein enhanceosome complex on the promoter
(25, 47, 56). While the ability of poly(I-C) and viral infection to
induce IFN- and - transcription is well established, no sig-
naling pathways are known to cross talk with the pathway that
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leads to IFN- expression or to regulate the transcriptional
activation of IRF-3 or -7.
One signaling pathway, which engages in cross talk with
other signaling pathways and is involved in immune response
modulation, is initiated by the cytokine transforming growth
factor  (TGF-). TGF- is the prototype member of a large
family of structurally related growth and differentiation factors
that includes activins and bone morphogenetic proteins (11).
TGF-1 is prominently expressed in hematopoietic and im-
mune cells, and TGF-1 expression and activation are upregu-
lated at sites of tissue injury and in tumorigenesis (12, 14, 39,
82). At the cellular level, TGF- regulates proliferation, dif-
ferentiation, apoptosis, adhesion, motility, and extracellular
matrix deposition, and the effects are often cell type and con-
text dependent. Through its broad array of cellular activities,
TGF- regulates cell-fate determination, tissue homeostasis,
and wound healing and modulates many aspects of immune
functions (12, 39). TGF- also plays a critical role in the im-
mune response to pathogens, including viruses, bacteria, yeast,
and protozoa (61), and TGF-1 is transcriptionally induced
following viral infections, e.g., by cytomegalovirus (CMV) (27,
53, 91), human immunodeficiency virus type 1 (24, 30), and
hepatitis B (92). Many studies suggest that TGF- has a neg-
ative influence on the host response and a beneficial effect on
the survival and growth of intracellular pathogens (61). How-
ever, other studies correlate TGF- with enhanced resistance
to microbes (51, 52, 74). Consistent with its context-dependent
effect on many cellular functions, the complex role of TGF- in
the host defense against pathogens remains to be fully charac-
terized.
The Smads act as intracellular effectors of gene expression
responses to TGF-, and a general model for how TGF-
signaling activates transcription of target genes has been es-
tablished (13, 33, 50, 55, 71). At the cell surface, TGF- binds
to a complex of type I and type II transmembrane receptor
serine/threonine kinases, resulting in transphosphorylation and
consequent activation of the type I receptor by the type II
receptor kinase. The activated type I TGF- receptors phos-
phorylate Smad2 and Smad3 at C-terminal serines, and these
receptor-activated Smads then form a complex with Smad4.
The TGF--activated, heteromeric Smad complexes then
translocate into the nucleus, where they induce or repress
transcription of defined genes. While most Smads have the
capacity to bind DNA at a favorable sequence context, the
receptor-activated Smads naturally activate transcription
through physical interaction and functional cooperation with
transcription factors with defined DNA sequence binding (33,
50, 71, 79, 98). For example, the TGF--activated Smad3 can
cooperate with the basic leucine zipper protein c-Jun (43, 60,
84, 97), the basic helix-loop-helix protein TFE3 (31, 32), the
Zn finger protein Sp1 (8, 20, 58), and AML/RUNX transcrip-
tion factors (28, 57, 99), depending on the target gene. The
receptor-activated Smads also interact through their C termini
with CBP or p300, two closely related coactivators (19, 34, 69,
80). This interaction is stabilized by Smad4, providing a mech-
anism by which Smad4 acts as a Smad coactivator (19).
We now provide evidence that Smad3 physically and func-
tionally interacts with IRF-7 and that TGF-/Smad3 signaling
regulates the transcriptional activity of IRF-7 at the IFN-
promoter. Our results strongly suggest that the transcriptional
activation of the IFN- gene by IRF-7 depends on and is
regulated by the endogenous level of TGF--activated Smad3.
MATERIALS AND METHODS
Yeast two-hybrid screen and identification of IRF-7. The LexA-based Saccha-
romyces cerevisiae two-hybrid system (26, 93) was used to screen for proteins that
specifically interact with Smad3. Full-length, Flag-tagged human Smad3 in the
bait plasmid pEG202 (85) and a cDNA library derived from HeLa cell mRNA in
the prey plasmid pJG4-5 were transformed into yeast EGY48 by using the Alkali
Cation kit (Bio 101, Inc.). Protein-protein interactions were determined by scor-
ing -galactosidase activity on 5-bromo-4-chloro-3-indolyl--D-galactoside plates
containing galactose or glucose.
Expression plasmids. Smad2, -3, and -4 and the Smad3 deletion mutants
Smad3C and Smad3C were expressed as Flag-tagged proteins from the CMV
promoter in pRK5 expression plasmids (96, 97). The constitutively active TRI
and TRII chimera, R(II-I)C, and the dominant-negative TRII, RII-DN, have
been described previously (6, 18). Full-length IRF-7 was expressed as an N-
terminally Flag-tagged or C-terminally Myc-tagged version. The DNA fragments
encoding wild-type human IRF-7 were generated by PCR using pcDNA-IRF-7A
(94) as a template and inserted into the BamHI-SalI sites of the mammalian
expression vectors pXF1F and pRK5M (17), thus generating pXF1F-IRF-7 and
pRK5M-IRF-7, respectively. pRK5M-IRF-7 N417 contains the N-terminal
amino acids 1 to 417 of IRF-7 and was expressed as a C-terminally Myc-tagged
protein. The DNA fragments encoding the N417 segment were excised from
pRK5M-IRF-7 by EcoRI and ligated into the EcoRI sites of pRK5M.
pXF1M-IRF-7 C415, containing amino acids 415 to 503, was generated by
digesting pXF1F-IRF-7 with EcoRI-SalI, and the corresponding 0.3-kb fragment
was ligated into EcoRI-SalI sites of expression vector pXF1M. Full-length hu-
man IRF-3 was expressed as an N-terminally Myc-tagged protein. The DNA
fragments encoding wild-type IRF-3 were generated by PCR using pHA-IRF-3
(35), provided by P. M. Pitha (The Johns Hopkins University School of Medi-
cine, Baltimore, Md.), as a template and inserted into the EcoRI-SalI sites of the
mammalian expression vector pXF1M (17). The murine IRF-7 coding sequence
with EcoRI and XhoI recognition sites was generated by PCR using pBabe/His-
tag-IRF-7 (64) as a template and inserted into the EcoRI-SalI sites of pXF1M.
All expression plasmids were verified by DNA sequencing.
In vitro GST protein binding assay. Plasmids that direct expression of gluta-
thione S-transferase (GST)-fused Smad2, -3, and -4 and Smad3NL in Escherichia
coli have been described elsewhere (97). The Smad proteins fused to GST were
expressed in E. coli and semipurified by glutathione-Sepharose 4B adsorption
according to the manufacturer’s recommendations (Amersham-Pharmacia Bio-
tech). 35S-labeled IRF-7 was generated by in vitro transcription from the pRK5-
based expression vector described above and translation in the presence of
[35S]methionine. In vitro protein binding assays to test the ability of the radio-
labeled IRF-7 to interact with GST-fused Smads were performed as described
previously (60). Specifically associated proteins were separated by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by
autoradiography. Parallel Coomassie blue staining revealed the integrity and
loading of the GST fusion proteins.
Luciferase reporter plasmids. The p-125Luc plasmid contains the 125 to
19 segment of the human IFN- gene promoter, which drives the expression of
a luciferase reporter (88). The p-125AALuc reporter is identical, except that it
contains mutations in the NF-B-binding sequence, PRDII (89). Both plasmids
were obtained from T. Fujita (The Tokyo Metropolitan Institute of Medical
Science, Tokyo, Japan). The reporter plasmid p31x2-Luc, containing two copies
of PRDIII-PRDI sequences of human IFN-, was made by ligation of oligonu-
cleotides corresponding to the PRDIII-PRDI sequences into the HindIII site of
the minimal TATA box promoter, pTA-Luc (99). The oligonucleotides used
were the following: sense, 5 AGC TTA GGA AAA CTG AAA GGG AGA
AGT GAA AGT GA 3; antisense, AGC TTC ACT TTC ACT TCT CCC TTT
CAG TTT TCC TA 3. The corresponding mutant reporter, pm31x2-Luc, was
similarly created by ligating the mutant oligonucleotides (lowercase letters de-
note mutations) with the following sequences: sense, 5 AGC TTA GGA gcA
CTG AAA GGG AGA AGT GAg cGT GA 3; antisense, AGC TTC ACg cTC
ACT TCT CCC TTT CAG Tgc TCC TA 3. All other promoter mutants were
made by two-round PCR-based mutagenesis. First, a 5 vector primer together
with a primer containing specific mutations were used to generate the fragment
containing the desired mutations, and then this fragment was used as a primer
together with a 3-vector-specific primer to produce the second fragment. The
final PCR product was digested with HindIII/SalI and ligated into the HindIII/
SalI sites of p-125Luc. These mutant reporters were generated using the follow-
ing mutation-containing primers: (i) mPRDIV-Luc reverse, 5 GTT TTC CTA
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TGT CcT TTA CAT TTT AGT AG 3 (98G primer; following reference 16);
(ii) mPRDIII-Luc reverse, 5 CAC TTC TCC CTT TCA GTg cTC CTA TGT
CAT TTA C 3 (88G/87C primer); (iii) mPRDIII-mPRDI primer reverse, 5
GGA ATT TCC CAC gcT CAC TTC TCC CTT TCA GTg cTC CTA AGT CAT
TTA C 3 (68G/67C/88G/87C primer). All promoter mutants were ver-
ified by DNA sequencing.
Cells and cell culture. Mouse embryonic fibroblasts (MEFs) from Smad3
knockout mice and wild-type littermates (9), obtained from X.-F. Wang (Duke
University Medical School, Durham, N.C.), were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 15% fetal bovine serum
(FBS), 100 IU of ampicillin/ml, and 100 g of streptomycin/ml (1	 P/S). HeLa
cells, HepG2 cells, COS1 cells, and the ecotropic retroviral packaging cell line
Phoenix E (obtained from G. Nolan, Stanford University) were maintained in
DMEM supplemented with 10% FBS and 1	 P/S. All cells were routinely
maintained at 37°C in the presence of 5% CO2.
Transient transfections and luciferase reporter assays. Transient transfec-
tions of HeLa and HepG2 cells were performed in six-well tissue culture plates
using Fugene 6 according to the manufacturer’s instructions (Roche). For each
transfection, 0.5 g of the luciferase reporter plasmid and, when indicated, 0.1
g of the Smad expression plasmid and 8 to 10 ng of the IRF-7 expression
plasmid were used. The total amount of transfected DNA was kept constant by
adding empty pRK5 vector, as needed. Cotransfection of 20 ng of the -galac-
tosidase expression plasmid (pRK5--Gal) allowed all transfections to be nor-
malized to the -galactosidase activity. TGF- treatment and luciferase assays
were carried out as described elsewhere (17). All experiments were carried out
in duplicate and repeated at least three times.
To evaluate the effect of poly(I-C) on IRF-7 activity, we transfected HeLa cells
with 0.25 g of the reporter plasmid p31x2-Luc, 10 ng of pRK5--Gal, and
different amounts of IRF-7 expression plasmid using Fugene 6 (Roche). At 12 h
after transfection, cells were incubated with 50 g of poly(I-C)/ml and DEAE
dextran (400 g/ml) in phosphate-buffered saline (PBS) for 2 h, then washed with
PBS and incubated with DMEM with 2% FBS. At 24 h later, luciferase assays
were performed as described previously (17).
Immunoprecipitation and Western blot analyses. COS1 cells were transfected
with expression plasmids for Flag-tagged Smads and Myc-tagged IRF-7 or de-
rivatives, using Lipofectamine (GIBCO-BRL) according to the manufacturer’s
instructions. At 48 h posttransfection, cells were lysed in MLB buffer consisting
of 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, and Complete
protease inhibitors (Roche). Cell lysates were precleared with anti-mouse im-
munoglobulin G (IgG; Jackson Laboratories) and protein A-Sepharose 4B (Am-
ersham-Pharmacia), and immunoprecipitations were performed using the M2
anti-Flag monoclonal antibody (Sigma) or anti-Myc 9E10 antibody (Covance).
Immunoprecipitated proteins were subjected to SDS-PAGE, transferred to poly-
vinylidene difluoride membrane (Perkin-Elmer), and blotted with anti-Myc 9E10
(Covance) or anti-Flag M2 (Sigma) antibodies. Proteins bound with antibodies
were visualized using enhanced chemiluminescence (ECL; Amersham-Pharma-
cia).
For IRF-7/Smad3 endogenous interaction, HeLa cells were grown to 
80%
confluence in 150-mm tissue culture dishes. Cells were washed once with PBS
and then placed in PBS containing 0.4 mg of DEAE-dextran/ml, 50 g of
poly(I-C) (Amersham-Pharmacia)/ml with or without 5 ng of TGF-/ml. After
2 h at 37°C, cells were harvested and processed as described previously (72)
except that the lysis buffer consisted of 1% NP-40, 50 mM Tris (pH 8.0), 137 mM
NaCl, and protease inhibitor cocktail (Roche). Lysates clarified by 20 min of
centrifugation in a microcentrifuge at 20,800 	 g were then immunoprecipitated
either with rabbit anti-mouse IgG (Jackson ImmunoResearch) or rabbit anti-
Smad3 (Zymed) and protein A-Sepharose. Immunoprecipitated proteins were
separated on SDS-PAGE. Western blotting was performed using anti-IRF-7
antibody (Santa Cruz). Bands were visualized using ECL reagents (Amersham-
Pharmacia).
In vivo [32P]phosphate labeling. MEFs were transfected with XF1M-mIRF-7
to express Myc-tagged murine IRF-7. At 12 h after transfection, cells were
incubated in phosphate-free DMEM with 0.2% FBS for 3 h and then incubated
with 1 mCi of [32P]orthophosphate/ml. Five micrograms of poly(I-C) and Lipo-
fectamine mix or Lipofectamine alone was added to cultures 1 h later, and cells
were incubated for 4 h. Cells were lysed, and whole-cell lysates were subjected to
immunoprecipitation. The immunoprecipitated proteins were separated by
SDS–6% PAGE. Results were visualized by autoradiography.
Biotinylated DNA affinity precipitation. Cell lysates were incubated with 15
nmol of biotinylated double-stranded oligonucleotides bound on streptavidin-
coated MagneSphere paramagnetic particles and 5 g of poly(dI-dC) at 4°C for
1 h. The paramagnetic particle/DNA/protein complexes were washed four times,
eluted in sample buffer, and separated on SDS-PAGE. Proteins that specifically
interacted with the DNA probe were detected by Western blotting as described
above.
Northern blotting and RT-PCR analyses. MEFs near 70% confluence were
treated with 50 g of poly(I-C)/ml and DEAE dextran (400 g/ml) in PBS for 2 h
and then washed with PBS and incubated with DMEM with 2% FBS. Total RNA
was isolated from the cells at the indicated times after addition of poly(I-C) using
the TRIzol kit (Life Technologies). A 15-g aliquot of total RNA was denatured
and electrophoresed in 1% formaldehyde–agarose gels and blotted onto Biotrans
nylon membranes (ICN). The cDNA for mouse IFN- was obtained from P. M.
Pitha and labeled with [-32P]dCTP using random primed labeling. Hybridiza-
tion with 32P-labeled DNA probes was performed at 65°C as described previously
(4). Results were visualized by autoradiography and quantified using a Phospho-
rImager (Molecular Dynamics). Reverse transcription-PCR (RT-PCR) of IRF-7
mRNA was performed using total RNA and the following primers: sense, 5-C
AGCGAGTGCTGTTTGGAGAC-3; antisense, 5-AAGTTCGTACACCTTA
TGCGG-3. Twenty-nanogram aliquots of RT products were used as templates
for PCRs.
Generation of stably infected cell lines. Stable cell lines infected with LPCX-
based retroviruses were established essentially as described previously (7). The
LPCX and LPCX-Smad3 retroviral constructs were previously described (7).
Briefly, Smad3/ MEFs were plated at 4 	 104 cells/well in six-well plates the
day before infection. To generate retroviruses, Phoenix E cells were transfected
with LPCX or LPCX-Smad3 plasmid DNA using the calcium phosphate method.
At 48 h after transfection, the conditioned medium containing retroviruses was
collected and filtered through 0.45-m-pore-size filters, supplemented with 8 g
of Polybrene (Sigma)/ml, and applied to Smad3/ MEFs. Cells infected with
the retroviruses were centrifuged at 1,800 rpm (GPR centrifuge; Beckman) for
45 min at room temperature. The viral supernatant was aspirated, fresh viruses
plus Polybrene were added to the cells, and the centrifugation procedure was
repeated. After infection, the cells were maintained in fresh growth medium at
37°C. At 48 h after infection, 2 g of puromycin (Calbiochem)/ml was used for
selection of stably infected cells.
Gal4 transactivation assays. To create the plasmid for IRF-7 fused to the Gal4
DNA-binding domain, the DNA fragment encoding IRF-7 was excised from
pXF1F-IRF-7 (described above) and ligated into the BamHI-SalI sites of the
mammalian expression vector pXF1Gal4, a pRK5 derivative with the Gal4 DNA
binding domain (amino acids 1 to 147) inserted between the ClaI/EcoRI sites of
pRK5 (19). The abilities of IRF-7 to transactivate the heterologous Gal4 pro-
moter reporter, pFR-Luc (Stratagene), were assayed as described elsewhere
(19).
RESULTS
Interaction of Smad3 with IRF-7. To better understand the
functions of TGF- in a broad array of cellular processes, we
sought to identify proteins that interact with Smad3, a key
effector of TGF- signaling, using a yeast two-hybrid screen
(26, 93) with full-length Smad3 as bait (85). One isolated
cDNA encoded the C-terminal amino acids 362 to 503 of the
human IRF-7 transcription factor (data not shown). This iden-
tification led us to characterize the physical and functional
interactions of the TGF--activated Smads with full-length
IRF-7, which was initially identified as IRF-7A (94).
To assess whether IRF-7 interacts directly with Smad3, we
evaluated the ability of in vitro-translated, 35S-labeled IRF-7 to
interact with Smad proteins fused to GST. These GST adsorp-
tion experiments revealed that Smad3 and Smad4 were able to
directly interact with IRF-7, whereas Smad2, which is also
activated by TGF-, displayed a much weaker interaction and
the GST segment alone did not interact (Fig. 1A). Thus,
among the TGF--activated Smads, Smad3 interacted effi-
ciently with IRF-7, while Smad2 had only a low affinity.
To evaluate the in vivo interactions between Smads and
IRF-7, we coexpressed Myc-tagged IRF-7 with Flag-tagged
Smads in transfected COS cells, which allow high levels of
transfection and expression yet have poor TGF- responsive-
ness. Cell lysates were subjected to immunoprecipitation using
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anti-Flag antibodies followed by Western blotting with anti-
Myc antibodies to detect the association. As shown in Fig. 1B,
IRF-7 coprecipitated with Smad3 and Smad4 in anti-Flag im-
munoprecipitation experiments. The less-efficient interaction
of Smad2 with IRF-7 was consistent with the weaker interac-
tion in the GST adsorption assays. In contrast to IRF-7, IRF-3
did not detectably interact with Smad3 but was able to interact
with Smad2 (Fig. 1C). IRF-7 and IRF-3 both interacted with
Smad4 (Fig. 1B and C). Finally, as shown in Fig. 1D, Smad3
also interacted with IRF-7 at endogenous levels in HeLa cells,
which express low levels of IRF-7 (data not shown). TGF-
treatment did not enhance the Smad3–IRF-7 interaction,
which was likely due to similar distributions of IRF-7 and
Smad3 in both nuclear and cytoplasmic fractions in the ab-
sence or presence of TGF- and the poor responsiveness of
HeLa cells to exogenous TGF- (data not shown).
Defining the domains of Smad3 and IRF-7 that mediate the
physical association. To define which segment of Smad3 in-
teracts with IRF-7, we tested the interactions of several Smad3
deletion mutants with IRF-7 in coimmunoprecipitation assays
(Fig. 2A). Deletion of the MH1 domain and the linker region
of Smad3 still allowed the MH2 domain (Smad3C) to effi-
ciently interact with IRF-7. Deletion of the C-terminal 43
amino acids, which are required for Smad trimerization and
transcriptional activity (70, 85, 96), in the Smad3CC segment
did not affect the interaction with IRF-7. Smad3NL, which
comprises the MH1 domain and linker segment, did not inter-
act with IRF-7. Accordingly, Smad3NL did not interact with
FIG. 1. IRF-7 interacts with Smad3 in vitro and in vivo. (A) Direct interaction of 35S-labeled, in vitro-translated IRF-7 with GST-Smad fusion
proteins, but not GST. Interacting IRF-7 was visualized following electrophoresis and autoradiography. IRF-7 interacted with Smad3 and 4, and
to a lesser extent with Smad2. The lower panel represents Coomassie blue-stained gels showing equal loading of the fusion proteins. (B) Interaction
of Smad3 with IRF-7 in vivo. COS1 cells were transfected with Flag-tagged Smads and Myc-tagged IRF-7. Cell lysates were immunoprecipitated
(IP) with anti-Flag antibody, followed by immunoblotting (IB) with anti-Myc antibody to detect Smad-bound IRF-7. IRF-7 interacted efficiently
with Smad3 and -4 and less efficiently with Smad2. (C) Interaction of Smads with IRF-3 in vivo. COS1 cells were transfected with Flag-tagged
Smads and Myc-tagged IRF-3, and cells were processed as described for panel B. IRF-3 did not interact with Smad3, and it interacted efficiently
with Smad4 and less efficiently with Smad2. Nonspecific IgG bands are visible in all lanes. The lower portions of panels B and C show the expression
levels of the transfected proteins in the lysates, as assessed by immunoblotting. (D) Endogenous IRF-7 and Smad3 interact. HeLa cells were
subjected to anti-Smad3 immunoprecipitations followed by Western blotting with anti-IRF-7. In a control experiment, the anti-Smad3 antibody was
replaced with anti-mouse IgG.
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IRF-7, while full-size Smad3 did, in GST adsorption assays
(Fig. 2B). We conclude that Smad3 interacts through its MH2
domain with IRF-7.
The IRF-7 segment that interacted with Smad3 in the yeast
two-hybrid screen corresponded to the C-terminal amino acids
362 to 503. We generated a further truncation of that segment
and, as shown in Fig. 2C, the C-terminal segment of IRF-7,
containing amino acids 415 to 503, in the IRF-7 C415 mutant
retained the ability to interact with Smad3. Truncation of
amino acids 418 to 503 in the IRF-7 N417 mutant almost
completely abolished the interaction of IRF-7 with Smad3.
These data indicate that amino acids 415 to 503 of IRF-7 are
sufficient and required for efficient interaction with Smad3
(Fig. 2D). This segment of IRF-7 corresponds to the signal-
regulated domain of IRF-7, preceded by part of its inhibitory
domain, and represents most of the sequence that is involved
in IRF-7 homodimerization or heterodimerization with IRF-3
(3, 45, 66). Since this segment of IRF-7 is also part of its
transactivation domain, we conclude that Smad3 and IRF-7
interact with each other through sequences in their transacti-
vation domains.
Smad3, but not Smad2, cooperates with IRF-7 to activate
transcription from the IFN- promoter. IRF-7 functions as
both a transcriptional activator and repressor, depending on
the promoter context (76, 94, 95). To date, the best-character-
ized function of IRF-7 is its role in transcriptional induction of
the IFN- and - genes following viral infection. Similar to
IRF-7, IRF-3 also plays a critical role in transcriptional acti-
vation of the IFN- gene (25, 66, 76–78). We therefore studied
the effects of ectopically expressed Smads on the transcrip-
tional regulation of the IFN- promoter by IRF-7 using a
luciferase reporter, p-125Luc (88). This plasmid contains the
luciferase reporter gene under the control of the 125 to 19
segment of the human IFN- promoter and is commonly used
FIG. 2. The interaction of IRF-7 and Smad3 is mediated by the C-terminal domains of both proteins. (A) Smad3C, but not Smad3NL, interacts
with IRF-7. COS1 cells were transfected with Flag-tagged Smad3 deletion mutants and Myc-tagged IRF-7. Cell lysates were subjected to
immunoprecipitation with anti-Flag antibody as described in the legend for Fig. 1, followed by Western blotting (IB) using the antibodies indicated.
The relative positions of the different Smad3 proteins are marked with an asterisk in the bottom panel. These results demonstrate an interaction
of the MH2 domain of Smad3 with IRF-7. (B) Direct interaction of 35S-labeled, in vitro-translated IRF-7 with GST-Smad fusion proteins.
Interacting IRF-7 was visualized following electrophoresis and autoradiography. The lower panel represents Coomassie blue-stained gels showing
equal loading of the fusion proteins. IRF-7 interacted with Smad3, but not with Smad3NL. (C) Smad3 interacted with IRF-7 C415, i.e., amino acids
415 to 503 of IRF-7. COS1 cells were transfected with Myc-tagged IRF-7 deletion mutants and Flag-tagged Smad3, and cell lysates were subjected
to immunoprecipitation with anti-Myc antibody, similar to the experiment shown in panel A. (D) Schematic diagram of Smad3 and IRF-7 and of
the deletion mutants used in panels A and C. The interacting protein segments in Smad3 and IRF-7 are shown.
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to study the transcriptional regulation of the IFN- gene (88,
89). Consistent with previous observations (45), expression of
IRF-7 activated transcription from the IFN- promoter in
transfected HeLa cells (Fig. 3A). In the absence of coexpressed
IRF-7, Smad2 did not activate transcription from the p-125Luc
promoter, whereas Smad3 expression provided a moderate
transcriptional activation. Coexpression of Smad3, but not
Smad2, strongly enhanced the transcriptional activation of the
IFN- promoter by IRF-7 (Fig. 3A). Smad2 decreased the
IRF-7-mediated transcription, reminiscent of the antagonism
between Smad2 and Smad3 at the goosecoid promoter (37). A
similar but weaker cooperation of Smad3 with IRF-7 was also
observed in HepG2 cells (data not shown; see Fig. 5C).
Since receptor-activated Smads often form heteromeric
complexes with Smad4, we also examined the effect of Smad4
on the transcriptional activation by IRF-7. Smad4 alone did
not enhance transcription, but coexpression of Smad4 with
IRF-7 consistently displayed a slightly higher transcriptional
activity than that observed with IRF-7 alone (Fig. 3A). Coex-
pression of Smad4 did not further enhance the Smad3/IRF-7
cooperativity and did not significantly affect the inhibitory ef-
fect of Smad2 (Fig. 3A).
In contrast to IRF-7, IRF-3 exerted only a low level of
transcriptional activation from the p-125Luc promoter, which
is likely explained by its stringent dependence on virus activa-
tion (42, 90). This low activity was only minimally, if at all,
enhanced by Smad3 or -4 (Fig. 3B). Together, these results
indicate that Smad3, but not Smad2, selectively cooperates
with IRF-7 to activate transcription from the human IFN-
promoter.
The IRF-7/IRF-3 binding sequences, PRDIII-PRDI, are nec-
essary and sufficient to mediate the cooperation between
Smad3 and IRF-7. The 125 to 19 segment of the human
IFN- promoter contains four PRDs for transcriptional acti-
vation, named PRDI through PRDIV. Among these, PRDIII
and PRDI are recognized by IRF-7 and IRF-3 (47, 76). PRDII
is a binding site for the transcriptional activator NF-B, com-
posed of p65 and p50, while PRDIV interacts with a het-
erodimer of the basic leucine zipper proteins ATF-2 and c-Jun
(47). Since Smad3 has been reported to functionally cooperate
with c-Jun (43, 60, 84, 97), ATF-2 (63), and NF-B (36, 46) in
other promoter contexts, we examined whether the transcrip-
tional cooperation of Smad3 and IRF-7 depended on these
transcription factors.
As a first approach, we selectively inactivated these different
binding sites in the 125 to 19 promoter segment by intro-
ducing mutations which abolished binding of the correspond-
ing transcription factors without affecting the other binding
sites. These mutant versions of p-125Luc were transfected into
HeLa cells, and the transcriptional cooperation of IRF-7 and
Smad3 was evaluated. As shown in Fig. 4A, inactivating mu-
tations in the PRDII (16) or PRDIV (88) sites decreased the
transcriptional activation by IRF-7, yet did not affect the co-
operation of IRF-7 and Smad3. Two base substitutions in the
highly conserved GAAA motif in the PRDIII sequence, one of
the IRF-3/IRF-7 binding sites (44, 65), strongly decreased the
transactivation by IRF-7 but did not abolish the transcriptional
cooperation of IRF-7 and Smad3. However, inactivating mu-
tations in both the PRDIII and PRDI sequences for IRF-3/
IRF-7 binding (44, 65, 83) abolished the transcriptional acti-
vation by IRF-7 as well as the cooperation of Smad3 and
IRF-7. These results indicate that the transcriptional cooper-
ativity of Smad3 and IRF-7 depends on the ability of IRF-7 to
interact with the PRDIII-PRDI sequence and that NF-B and
ATF-2/c-Jun binding to the promoter are not required for this
cooperation.
To further investigate whether the IRF-7-binding sequence
per se is sufficient to mediate Smad3–IRF-7 cooperation, we
generated an artificial luciferase reporter, p31x2-Luc, which
contains two tandem repeats of the PRDIII-PRDI sequence of
the human IFN- promoter upstream from a minimal TATA
box promoter. As seen with p-125Luc (Fig. 3A), IRF-7 acti-
FIG. 3. IRF-7, but not IRF-3, cooperates with Smad3 to activate the human IFN- promoter in HeLa cells. HeLa cells were transfected with
the p-125Luc reporter plasmid and expression plasmids for Smads, IRF-7 (A) or IRF-3 (B), as indicated. Forty hours after transfection, cells were
harvested and reporter activities were measured. Values, normalized for transfection efficiency, are shown as fold induction relative to basal
promoter activity as described in Materials and Methods. Note the much lower luciferase expression scale and values in panel B compared with
those in panel A.
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vated transcription from the PRDIII-PRDI sequence in HeLa
cells, while Smad2, -3, or -4 did not affect the basal level of
transcription (Fig. 4B). However, Smad3 and IRF-7 synergized
to induce transcriptional activation, which was much higher
than with IRF-7 alone. This transcriptional cooperativity was
not seen in the presence of Smad2, whereas coexpression of
Smad4 with IRF-7 resulted in a consistent minimal enhance-
ment above the IRF-7-mediated transcription (Fig. 4B). This
slight enhancement of IRF-7-mediated transcription by Smad4
was similar to what was seen with the p-125Luc promoter-
reporter plasmid (Fig. 3A). Inactivating mutations of the
IRF-7 binding sites in the pm31x2-Luc plasmid abolished both
the transcriptional activation by IRF-7 and cooperativity of
Smad3 with IRF-7 (Fig. 4C). Together, these results indicate
that the IRF-7 binding sites alone are sufficient and necessary
to mediate the cooperation of IRF-7 and Smad3.
The transcriptional cooperation of Smad3 and IRF-7 re-
sulted from the interaction of both transcription factors at the
PRDIII-PRDI sequence. Using DNA interaction assays with a
biotinylated oligonucleotide, we showed that IRF-7 interacted
with the PRDIII-PRDI sequence, as expected, and that this
interaction allowed recruitment of Smad3 to the DNA. Smad3
was unable to bind to this sequence in the absence of IRF-7
(Fig. 4D).
Dominant-negative interference with Smad3 function de-
creases IRF-7-mediated transcription. To begin to character-
ize the role of endogenous Smad3 in IRF-7-mediated tran-
scriptional activation, we assessed the effects of two Smad3
mutants, Smad3C and Smad3C, on the transcriptional acti-
vation of both the p-125Luc and p31x2-Luc reporters. These
assays were carried out in HeLa cells and HepG2 cells. HeLa
cells have only a low-level responsiveness to exogenous TGF-
FIG. 4. The PRDIII-PRDI sequences in the IFN- promoter are required and sufficient for Smad3/IRF-7 transcriptional cooperativity.
(A) Mutational analysis of the human IFN- promoter. PRDs were mutated individually, or in combinations, as depicted. The p-125Luc reporter
plasmid or mutant reporter plasmids were transfected into HeLa cells, along with expression plasmids for Smad3 and/or IRF-7, as indicated. The
transcriptional cooperation of Smad3 and IRF-7 was abolished following mutational inactivation of the PRDIII and PRDI sequences. (B) PRDIII-
PRDI sequences are sufficient to mediate IRF-7/Smad3 transcriptional cooperation. A reporter plasmid containing two copies of the PRDIII-
PRDI sequences of the IFN- promoter, p31x2-Luc, was transfected into HeLa cells with various expression plasmids, as indicated. Smad3, but
not the other Smads, strongly enhanced the transcription in the presence of IRF-7. (C) A reporter plasmid containing two copies of mutant
PRDIII-PRDI sequences, pm31x2-Luc, was unable to be activated by IRF-7 or IRF-7/Smad3. Luciferase activities were scored as for Fig. 3. Note
the much lower scale of luciferase activity compared to that in panel B. (D) DNA precipitation demonstrates the binding of IRF-7 to the p31x2
DNA sequence, but not to a mutated p31x2 sequence. Smad3 alone did not bind to the p31x2 sequence, but it did do so in the presence of IRF-7.
The lower panels show the expression levels of IRF-7 and Smad3 in the lysates.
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in transient-transfection reporter assays (reference 20 and data
not shown), while HepG2 cells are highly responsive to TGF-
(19, 20, 32, 63, 99). In addition, the endogenous expression of
TGF-1 by HepG2 cells (and HeLa cells) makes it likely that
they are subject to autocrine TGF- stimulation in the absence
of exogenous TGF-, as has been reported for other cell lines
(2, 7, 23, 54, 86).
The Smad3C mutant lacks the C-terminal 43 amino acids
of Smad3, which comprise the activating phosphorylation sites
(96). This C-terminal sequence is required for Smad trimer-
ization (5, 70, 85) and interaction with the CBP/p300 coacti-
vators (19). Overexpression of Smad3C has been shown to
interfere in a dominant-negative manner with Smad3-medi-
ated transcriptional activation (96). While Smad3 cooperated
with IRF-7 in HeLa cells at the p-125Luc and p31x2-Luc pro-
moters, Smad3C did not, and it slightly decreased the tran-
scription induced by IRF-7 (Fig. 5A and B). In HepG2 cells
(Fig. 5C and D), expression of Smad3C strongly repressed
the transcriptional activation of both promoters by IRF-7.
These results demonstrate that Smad3C does not cooperate
and interferes with IRF-7-mediated transcription in these as-
says. Its dominant-negative interference strongly suggests a
role for endogenous Smad3 in IRF-7-mediated transcription
from both the p-125Luc and p31x2-Luc promoters.
FIG. 5. Dominant-negative interference with Smad3 function inhibits transactivation by IRF-7. (A and B) The two dominant-negative mutants,
Smad3C and Smad3C, inhibited IRF-7-mediated transcription from p-125Luc (A) or p31x2-Luc (B) by IRF-7 in HeLa cells. HeLa cells were
transfected with p-125Luc or p31x2-Luc, along with expression plasmids for IRF-7, Smad3, or mutants, as indicated. Luciferase activities were
scored as described in the legend for Fig. 3. (C and D) Smad3C and Smad3C inhibited IRF-7-mediated transcription from p-125Luc (C) or
p31x2-Luc (D) in HepG2 cells. HepG2 cells were transfected with p-125Luc or p31x2-Luc, along with expression plasmids for IRF-7, Smad3, or
relevant mutants, as indicated. Twenty hours after transfection, cells were treated with (solid bars) or without (open bars) TGF-, and luciferase
activities were measured. Normalized luciferase activities are represented relative to those of control vector-transfected cells in the absence of
TGF-.
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We also evaluated the effect of Smad3C on IRF-7-mediated
transcription from both promoters. Smad3C corresponds to
the MH2 domain of Smad3, without its DNA-binding MH1
domain and linker segment, and is able to interact with IRF-7
(Fig. 2A). Overexpression of Smad3C has been shown to exert
strong transcriptional inhibition on TGF--responsive promot-
ers, presumably resulting from its sequestration of coactivator
CBP/p300 and/or titration of endogenous Smad3 and Smad4
(69). In HeLa cells, Smad3C was unable to cooperate with
IRF-7 to induce transcription from either promoter and re-
pressed the transcriptional activity of IRF-7 (Fig. 5A and B).
The interference effect of Smad3C was stronger than that of
Smad3C, although this may have been due to a higher ex-
pression level of Smad3C versus Smad3C (data not shown).
In the TGF--responsive HepG2 cells, Smad3C strongly re-
pressed both the basal level and TGF--induced level of IRF-
7-mediated transcription at either promoter (Fig. 5C and D).
Together, these data illustrate that endogenous Smad3 regu-
lates IRF-7-mediated transcriptional activation from the
PRDIII-PRDI sequence and strongly suggest that the level of
transcription activation induced by IRF-7 depends on the lev-
els of functional Smad3. Thus, interference with Smad3 func-
FIG. 6. IFN- mRNA induction by poly(I-C) depends on Smad3 expression. Induction of IFN- mRNA was monitored by Northern
hybridization. (A) Poly(I-C) treatment of MEFs induced expression of IRF-7 mRNA, as assessed by RT-PCR at the indicated times following
initiation of treatment. (B) Effect of poly(I-C) on IRF-7 labeled with [32P]orthophosphate in vivo. Poly(I-C) induced a mobility shift of 32P-labeled
IRF-7, as assessed after 4 h of treatment, similar to what is observed in response to viral infection. Similar results were also observed after 2 h of
treatment with poly(I-C) (data not shown). (C) Effect of poly(I-C) on the transcriptional activity of IRF-7 at the p31x2-Luc promoter/reporter.
Poly(I-C) enhanced the transcriptional activity of IRF-7 at different expression levels in transfected MEFs. The poly(I-C)-induced increase of
transcription in vector control MEFs was likely a reflection of endogenous IRF-3 and IRF-7 expression (A). (D) Smad3/ and matched normal
MEFs were treated with poly(I-C), and RNA was isolated at the indicated times following addition of poly(I-C). The absence of Smad3 delayed
and decreased early-phase IFN- induction. (E) Expression of Smad3 in Smad3/ cells, infected with the LPCX-Smad3 vector, conferred earlier
induction of endogenous IFN- expression in response to poly(I-C) treatment. LPCX-infected control cells and Smad3-expressing cells were
treated with poly(I-C), and total RNA was isolated at the indicated times after treatment. The top portions of panels D and E show IFN- mRNA
under the same exposure condition on the same X-ray film, while the lower portions of the panels show the ethidium bromide-stained gels.
(F) Expression of Smad3 in Smad3/ cells infected with the retroviral LPCX-Smad3 vector, as shown by Western blotting to detect Flag-tagged
Smad3.
VOL. 24, 2004 TGF-/Smad3 IN IRF-7-MEDIATED IFN- INDUCTION 1419
tion by Smad3C or Smad3C inhibits the transcriptional ac-
tivity of IRF-7.
Smad3 levels regulate the induction of endogenous IFN-
expression by poly(I-C). The transcriptional cooperation of
Smad3 and IRF-7, and the dominant-negative inhibition of
IRF-7 activity by Smad3C and Smad3C as outlined above,
suggested a possible role of Smad3 in the transcriptional reg-
ulation of endogenous IFN- expression. We therefore exam-
ined whether inhibition of Smad3 expression would affect the
induction of endogenous IFN- mRNA by poly(I-C), which
mimics the double-stranded RNA generated during viral in-
fection and strongly induces IFN- expression. In addition to
the constitutive expression of IRF-3, poly(I-C) also induced
IRF-7 expression in mouse embryonic fibroblasts (Fig. 6A).
Consistent with its ability to activate endogenous IRF-3 (25,
66, 67), poly(I-C) is thought to activate IRF-7 through phos-
phorylation, presumably through the activity of the PKR ki-
nase (15). We therefore evaluated the effect of poly(I-C) on
IRF-7 phosphorylation in vivo and on IRF-7 transcriptional
activity. We showed that poly(I-C) rapidly induced a mobility
shift of a fraction of IRF-7 (Fig. 6B) similarly to the mobility
shift of a fraction of IRF-7 in response to viral infection (73),
thus reflecting increased phosphorylation of IRF-7. Poly(I-C)
also enhanced the transcriptional activity of IRF-7 at the IRF-
3/IRF-7-specific p31x2 promoter, proportionally with the dif-
ferent expression levels of IRF-7 (Fig. 6C). The slight enhance-
ment by poly(I-C) of the basal transcription in the absence of
coexpressed IRF-7 most likely resulted from the endogenous
expression of IRF-3 and IRF-7 (Fig. 6A). Together with the
published observations (15), these results strongly suggest that
the induction of IFN- expression by poly(I-C) is mediated by
IRF-3/IRF-7 activation.
Having established the ability of poly(I-C) to activate IRF-7,
we examined whether inhibition of Smad3 expression would
affect the induction of endogenous IFN- mRNA by poly(I-C).
MEFs derived from Smad3/ mouse embryos (9) and wild-
type littermates were transfected with poly(I-C) (15), and total
RNA was isolated at different time points. The induction of
IFN- mRNA expression was determined by Northern blot
analysis (Fig. 6D). In normal MEFs, IFN- mRNA was readily
detectable after 2 h and, following a lag phase of several hours,
enhanced to reach peak induction at 8 to 10 h posttreatment.
In contrast, IFN- mRNA showed a much lower induction
level in the Smad3/ MEFs and perhaps a slight delay in
induction. It started being detectable at 4 h, was enhanced at
8 h, and reached peak induction at 10 h posttreatment (Fig.
6D). At 12 h, however, its expression was already significantly
declined in Smad3/ cells, whereas it still persisted at a high
level in wild-type MEFs. These data indicated that loss of
Smad3 expression overall decreased IFN- mRNA induction
by poly(I-C).
To confirm that this lower induction of IFN- expression by
poly(I-C) is caused by loss of Smad3 expression, we established
a derivative cell line of Smad3/ MEFs, i.e., Smad3//
FIG. 7. Smad3 and TGF- signaling regulate the transactivation function of IRF-7. (A) Smad3 and TGF- stimulated the transcriptional
activity of Gal4–IRF-7, and Smad3C and Smad3C inhibited it. TGF- enhanced the activity of Gal4–IRF-7. (B) Smad3 signaling and TGF-
signaling through the cytoplasmic TRI/RII chimera, R(II-I)C, stimulated the transcriptional activity of IRF-7, and a dominant-negative TRII,
RII-DN, inhibited it. HepG2 cells were cotransfected with Gal4–IRF-7 and the luciferase reporter pFR-Luc and expression plasmids for Smads
and TGF- receptors. Luciferase activities were scored as described for Fig. 5C and D.
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LPCX-Smad3 cells, which constitutively expresses Smad3 un-
der the control of a CMV promoter in the LPCX retroviral
vector (7). A control cell line which was infected with the
empty LPCX vector was also generated. Immunoblotting anal-
yses detected the expression of Smad3 in cells stably infected
with the Smad3 expression vector, but not in the empty vector
control cells (Fig. 6F). These stably transduced cells were used
to assess the role of Smad3 in the induction of IFN- by
poly(I-C). Consistent with our results with normal MEFs, ex-
pression of Smad3 in Smad3/ MEFs conferred a more rapid
and a higher induction of IFN- mRNA by poly(I-C), in com-
parison with control, LPCX vector-infected cells (Fig. 6E).
Smad3/TGF- signaling enhances the transactivation func-
tion of IRF-7. We next evaluated whether the ability of Smad3
to cooperate with IRF-7 was due to an inherent ability of
Smad3 to enhance the transcriptional activity of IRF-7. For
this purpose, we fused IRF-7 to the Gal4 DNA-binding do-
main to create a transcription factor that activates the expres-
sion of a luciferase reporter gene dependent on its binding to
multiple copies of a Gal4 DNA-binding sequence. This Gal4
transactivation assay enabled us to assess the effects of Smads
on the transcription activity of IRF-7, independent of its ca-
pacity to bind DNA.
As shown in Fig. 7A, expression of Smad3 enhanced the
transcription activity of IRF-7. In contrast, coexpression of
Smad2 or Smad4 did not affect the activity of Gal4–IRF-7.
Furthermore, expression of Smad3C and Smad3C decreased
the activity of Gal4–IRF-7. These data illustrate that the tran-
scription activity of IRF-7 depends on the Smad3 activity lev-
els. The inability of Smad2 and Smad4 to affect the transcrip-
tional activity of Gal4–IRF-7 is consistent with the lack of
cooperation of Smad2 and the very low level of cooperation of
Smad4 with IRF-7 at the p-125Luc promoter (Fig. 3A) and
p31x2-Luc promoter (Fig. 4B). These data also explain why
Smad3C and Smad3C dominantly inhibit the IRF-7 activity at
these two promoters (Fig. 5).
We further assessed the effect of TGF- on the transcription
activity of Gal4-fused IRF-7. As shown in Fig. 7, TGF- en-
hanced the transcription activity of Gal4–IRF-7, and this en-
hancement was further increased in the presence of Smad3. In
contrast, TGF--mediated enhancement was inhibited by over-
expressing the dominant-negative Smad3C or Smad3C mu-
tants (Fig. 7A). Furthermore, expression of the constitutively
active chimeric TGF- receptor R(II-I)C, in which the TRII
and TRI cytoplasmic domains are covalently linked with an
intervening linker sequence (18), further enhanced the tran-
scriptional activity of IRF-7 (Fig. 7B).
Conversely, we examined the effect of perturbation of
TGF- receptor signaling on the transcriptional activity of
Gal4–IRF-7. As shown in Fig. 7B, dominant-negative interfer-
ence with TGF- signaling through expression of RII-DN,
which contains only the extracellular domain and the trans-
membrane domain of the type II TGF- receptor without its
cytoplasmic domain (6), decreased the transcriptional activity
of Gal4–IRF-7 and blocked TGF--induced transcriptional ac-
tivation of IRF-7.
TGF- signaling enhances transcription from the IFN-
promoter. The effect of TGF-/Smad3 signaling on the trans-
activation function of Gal4–IRF-7 suggested that TGF- sig-
naling regulates the transcription from the IFN- promoter
through activation of Smad3. We therefore tested the effect of
TGF- on transcriptional activation of p-125Luc in HeLa and
HepG2 cells. HeLa cells have only a limited responsiveness to
exogenous TGF-, even though they display autocrine TGF-
responsiveness, while treatment of HepG2 cells with TGF-
activates transcription of TGF--responsive promoters. The
lack of a convincing effect of TGF- on the transcription from
the IFN- promoter in HeLa cells (data not shown) may have
been due to the low number of receptors and autocrine TGF-
signaling and, therefore, the limited ability of TGF- signaling
to activate endogenous Smad3, compared to the high level of
transfected reporter plasmid. We therefore assessed the regu-
FIG. 8. TGF- signaling enhances the transcriptional cooperation of IRF-7 and Smad3 at the IFN- promoter. (A) TGF- receptor signaling
increased Smad3–IRF-7 cooperativity in HeLa cells. HeLa cells were transfected with p-125Luc and expression plasmids for IRF-7, Smad3, and
the cytoplasmic TRI/RII chimera, R(II-I)C. (B) TGF- enhanced and the dominant-negative TRII receptor inhibited transcription from
p31x2-Luc by IRF-7 in transfected HepG2 cells. (C) TGF- enhanced and the dominant-negative TRII receptor inhibited transcription from
p-125Luc by IRF-7 in transfected HepG2 cells. Luciferase activities were scored as described in the legend for Fig. 3.
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lation of the transfected p-125Luc reporter by TGF- signaling
using the cotransfected chimeric TGF- receptor protein R(II-
I)C. As shown in Fig. 8A, the R(II-I)C chimera cooperated
with Smad3 and IRF-7 to activate transcription from the
p-125Luc promoter. Additionally, the cooperation of Smad3
with IRF-7 was further enhanced by coexpression of R(II-I)C.
These results suggest that activation of Smad3, as a result of
TGF- signaling, enhances the cooperativity of both endoge-
nous and cotransfected Smad3 with IRF-7.
We further assessed the role of TGF- signaling in the
regulation of IFN- expression by IRF-7 in HepG2 cells both
using the dominant-negative type II TGF- receptor, RII-DN,
and in response to exogenous TGF-. As shown in Fig. 8B,
IRF-7 activated transcription from the p31x2-Luc promoter,
and this activity was enhanced in response to added TGF-.
The basal IRF-7 activity in the absence of added TGF- was
decreased by blocking the type II receptor signaling, i.e., in the
presence of RII-DN, which is consistent with autocrine TGF-
signaling in these cells. RII-DN also blocked the response to
exogenous TGF-. Similar results were observed using the
p-125Luc promoter in HepG2 cells (Fig. 8C). These results
further indicate that TGF- signaling, both exogenously and
through autocrine signaling, is a major determinant of the
IRF-7 activity at the IFN- promoter.
DISCUSSION
The rapid induction of IFN- and - plays a key role in the
cell’s response against viral infection. Extensive studies have
focused on the mechanisms of transcriptional induction of
these IFN genes following viral infection, and they have re-
vealed that IRF-3 and IRF-7 are essential for transcriptional
activation of the IFN- gene (25, 41, 42, 77, 78). However, it is
not known whether IFN- expression, or the activity of IRF-7
or IRF-3, are regulated through cross talk with other signaling
pathways. We now provide evidence that TGF- signaling reg-
ulates the transcription activity of IRF-7 through direct inter-
action and functional cooperation of Smad3 with IRF-7. The
regulation of the IRF-7 function by TGF-/Smad3 at the
IFN- promoter suggests a possible role for TGF-/Smad sig-
naling in the induction of IFN- expression and possibly in the
innate immune response.
TGF-/Smad3 regulates IRF-7 function. The conclusion
that Smad3 regulates IRF-7-mediated transcription is based on
mutational analysis of the IFN- promoter and on physical and
functional interaction studies. The 125-bp IFN- promoter
segment used in our assays contains binding sequences for
c-Jun/ATF-2 (16), NF-B (22, 38, 81), and IRF-3/7 (44, 83).
Since TGF-/Smad3 signaling can cooperate with c-Jun (45,
60, 84, 97), ATF-2 (63), and NF-B (36, 46) at other promot-
ers, we addressed the contributions of these binding sequences
in transcriptional activation. Inactivation of the PRDII se-
quence, which is able to bind NF-B, did not affect the tran-
scriptional activation by IRF-7 and cooperation with Smad3.
Inactivation of the PRDIV sequence, which binds c-Jun/
ATF-2, decreased the overall level of transcriptional activation
but did not affect the cooperation of IRF-7 and Smad3 either.
However, mutational inactivation of the PRDIII-PRDI se-
quence, i.e., the IRF-3/IRF-7 binding site, abolished both the
induction by IRF-7 and the cooperation of Smad3 and IRF-7
(Fig. 4A). Furthermore, two tandem copies of the PRDIII-
PRDI sequence in the minimal reporter plasmid p31x2-Luc
fully supported the cooperation of IRF-7 and Smad3, and
mutation of the IRF-7 binding site in this reporter abolished
the cooperation (Fig. 4B and C). Together, these data dem-
onstrate that the PRDIII-PRDI sequence is required and suf-
ficient for IRF-7/Smad3 cooperation at the IFN- promoter,
and they raise the possibility that IRF-7/Smad3 cooperation
regulates transcription from other promoters.
In addition to the cooperation of Smad3 with IRF-7 and the
enhancement of the transcription activity of IRF-7 by Smad3
(Fig. 3, 4, 5, and 7), two dominant-negative mutants of Smad3,
i.e., Smad3C and Smad3C, repressed IRF-7-mediated pro-
moter activation (Fig. 5) and the transactivation of Gal4–
IRF-7 (Fig. 7A). While Smad3C may sequester CBP/p300 and
endogenous Smads (69), its mechanism of dominant-negative
interference on IRF-7 function may also resemble that of an
IRF-7 C-terminal segment. The C terminus of IRF-7 mediates
the interactions with IRF-7 or IRF-3 and, when expressed
alone, interferes with IRF-7 activity through the formation of
a nonfunctional IRF-7 complex (3). Since the MH2 domain of
Smad3 interacts with the C-terminal segment of IRF-7 (Fig. 2),
both the MH2 domain of Smad3 and the C-terminal domain of
IRF-7 may interfere with the IRF-7/Smad3 complex formation.
In this regard, it is worth noting that that the C-terminal
domains of IRF-3, which is closely related to IRF-7, and Smads
share considerable similarity in their three-dimensional struc-
tures (59).
In our study, IRF-3 activated at a low level the transcription
from the PRDIII-PRDI sequence in p-125Luc (Fig. 3B) or
p31x2-Luc (data not shown), and Smad3 did not enhance IRF-
3-mediated transcription. The latter observation is consistent
with the lack of physical interaction of Smad3 and IRF-3 in
coimmunoprecipitation assays (Fig. 1C). However, our exper-
iments were performed in the absence of virus, and IRF-3
activation is dependent on virus infection; in contrast, IRF-7
has a basal activity in the absence of virus (45, 66, 67, 90). We
therefore do not exclude the possibility that virus-activated
IRF-3 may be regulated by Smad3. We are currently investi-
gating the role of TGF-/Smad3 signaling on virus-activated
IRF-3/IRF-7 function.
Consistent with the functional interaction of Smad3 with
IRF-7, TGF- signaling regulates IRF-7 function. This regu-
lation is illustrated by the ability of a dominant-negative
TGF- receptor to strongly decrease the transactivation func-
tion of IRF-7 fused to a Gal4 DNA-binding domain (Fig. 7B)
and to decrease the transcription activity of IRF-7 at the IFN-
and p31x2 promoters (Fig. 8B and C) and by the ability of
added TGF- to enhance IRF-7-mediated transcription from
the IFN- and p31x2 promoters (Fig. 8B and C). In addition,
enhanced TGF- signaling through a constitutively active re-
ceptor chimera strongly stimulated IRF-7 function and the
IRF-7/Smad3 cooperation at the IFN- promoter (Fig. 7B and
8A). Thus, the function of IRF-7 is regulated by both the
autocrine responsiveness to endogenous TGF-, observed in
most cells in culture, and the response to exogenous TGF-.
Our present findings that Smad3 physically associates and
functionally cooperates with IRF-7 present a new angle in our
understanding of the mechanism of action of IRFs. They indi-
cate that the transcription function of IRF-7 is regulated by
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TGF-/Smad3 signaling and that IRF-7 can activate transcrip-
tion through interaction with another class of transcription
factors, i.e., the Smads.
Mechanism of IRF-7 regulation by Smad3. Smads, espe-
cially Smad3, interact and synergize with several types of DNA
binding transcription factors (33, 50, 79, 98). The direct inter-
action and functional cooperation of Smad3 with IRF-7 are
consistent with this model for Smad-mediated transcriptional
activation, yet extend it to another class of transcription fac-
tors. Since Smad3 enhances the DNA binding of certain tran-
scription factors, e.g., Sp1 (20, 58), CBFA1 (1), and c-Jun (J.
Qing and R. Derynck, unpublished results), we evaluated the
effect of Smad3 on the DNA binding of IRF-7. However,
IRF-7 binding to the PRDIII-PRDI sequence was not affected
by the presence of Smad3, as assessed using an electrophoretic
mobility shift assay and DNA precipitation, and Smad3 by
itself did not detectably bind to this DNA sequence (Fig. 4D
and data not shown). On the other hand, TGF-/Smad3 en-
hanced the transcriptional activity of IRF-7, as determined in
Gal4–IRF-7 transactivation assays, and dominant-negative
mutants of the TGF- receptor and Smad3 decreased the
transactivation by Gal4–IRF-7 (Fig. 7). The Smad3-mediated
increase of the transcriptional activity of Gal4–IRF-7 bears
similarity to the effect of Smad3 on the transcriptional activity
of Gal4-fused Sp1 (20, 58). Since Smad3 and other receptor-
activated Smads interact with CBP/p300 (19, 34, 69, 80) and
Sp1 does not (62), Smad3 is likely to enhance the activity of
Sp1 through its ability to recruit CBP/p300 in response to
TGF- (19). Considering the low-affinity interaction of IRF-7
for p300 (87), it is conceivable that the interaction of TGF--
activated Smad3 with CBP/p300 helps stabilize the recruitment
of CBP/p300 in the multiprotein transcription complex, thus
enhancing transcription in response to TGF-.
Role of Smad3/TGF- signaling in IFN- induction. The
regulation of the transcription activity of IRF-7 by Smad3
suggests a role for TGF-/Smad3 signaling in the induction of
IFN- expression. In the absence of viral infection, cells ex-
press IFN- at very low levels, most likely resulting from con-
stitutive expression of IRF-3 and a very low level of IRF-7 that
results from a spontaneous, low level of IFN-/ expression
and signaling (29, 77). Following viral infection, IFN- expres-
sion is rapidly induced and IRF-7, which has a short half-life,
plays a key role in this induction. A two-phase model of IFN-
induction suggests that IRF-3 is mainly responsible for the
initial inefficient induction of IFN- which, following receptor
binding, activates Jak-Stat signaling, thus leading to IRF-7
expression. IRF-7 then cooperates with IRF-3 to launch a
robust induction of IFN- expression (25, 41, 48, 64, 77). Based
on this model, the expression level and activity of IRF-7 play a
critical role in the maximal induction of IFN- through coop-
eration with constitutively expressed IRF-3. Therefore, the
ability of TGF-/Smad3 signaling to target the activity of
IRF-7 may impact IFN- expression in response to viral infec-
tion.
To evaluate the relevance of the regulation of IRF-7 by
TGF-/Smad3 signaling in endogenous IFN- induction, we
examined its induction in response to poly(I-C) in Smad3/
and wild-type fibroblasts. Poly(I-C) is thought to activate
IRF-3 (25, 66, 67) and induces IRF-7 expression (Fig. 6A). We
also observed that poly(I-C) rapidly induced a mobility shift of
in vivo 32P-labeled IRF-7 (Fig. 6B), similarly to what has been
reported for virus-activated IRF-7 (73), and activated the tran-
scription function of IRF-7 (Fig. 6C). The peak of IFN-
mRNA expression coincided with poly(I-C)-induced IRF-7 ex-
pression and was consistent with the poly(I-C)-induced activa-
tion of IRF-7. In these experiments, inhibition of Smad3 ex-
pression resulted in lower induction of IFN- expression
following poly(I-C) transfection (Fig. 6D), whereas reintroduc-
tion of Smad3 conferred an earlier onset and higher level of
induction (Fig. 6E). Although TGF-/Smad3 signaling regu-
lates IRF-7 function and transcription from the IFN- pro-
moter, we were unable to see a significant effect of TGF- on
the poly(I-C)-mediated induction of endogenous IFN-
mRNA expression in MEFs (data not shown). This lack of
detectable effect was likely primarily due to the low levels of
available TGF- receptors in these cells (data not shown), thus
allowing only a minimal effect of exogenous TGF- on activa-
tion of endogenous Smad3 in these cells, and our use of a very
robust protocol for induction of IFN-, i.e., poly(I-C) treat-
ment. Nevertheless, the endogenous Smad3 levels influenced
the induction of IFN- expression, presumably reflecting acti-
vation of Smad3 from autocrine TGF- receptor signaling.
While the exact mechanism of regulation of poly(I-C)-induced
IFN- expression by Smad3 requires further characterization,
our results nevertheless demonstrate an important role of
Smad3 in defining the quantitative regulation of IFN- expres-
sion in response to poly(I-C). Efforts to study the role of
TGF-/Smad3 signaling on virus-activated IRF-3/IRF-7 func-
tion and IFN- expression are under way.
In summary, considering the essential role of IRF-7 in the
induction of IFN- expression, our finding that TGF-/Smad3
signaling regulates the activity of IRF-7 suggests a role for
TGF-/Smad3 signaling in the induction of IFN- expression.
Since TGF- levels increase rapidly after viral infection, IFN-
induction is likely to depend on the endogenous Smad3 level,
the level of autocrine TGF-/Smad3 signaling, and the respon-
siveness of the cells to elevated TGF-. Future experiments
will address the dependence of the transcription activity of
IRF-7 and expression of IFN  and  upon viral infection on
TGF-/Smad3 signaling.
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37. Labbé, E., C. Silvestri, P. A. Hoodless, J. L. Wrana, and L. Attisano. 1998.
Smad2 and Smad3 positively and negatively regulate TGF--dependent tran-
scription through the forkhead DNA-binding protein FAST1/2. Mol. Cell
2:109–120.
38. Lenardo, M. J., C. M. Fan, T. Maniatis, and D. Baltimore. 1989. The
involvement of NF-B in -IFN gene regulation reveals its role as widely
inducible mediator of signal transduction. Cell 57:287–294.
39. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by
TGF-. Annu. Rev. Immunol. 16:137–161.
40. Levy, D. E., and J. E. Darnell, Jr. 2002. Stats: transcriptional control and
biological impact. Nat. Rev. Mol. Cell. Biol. 3:651–662.
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